Skip to main content

Table 5 Effect of cumulative rituximab dose on outcomes

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

 

Number

Relative risk

95%CI

lower limit

95%CI

upper limit

p value

Overall p value

Chronic GVHD

      

Rituximab dose (mg/m2)

      

 <1000

208

1

   

0.03

 1000–1999

110

0.64

0.46

0.90

0.01

 

 2000–3375

46

0.92

0.62

1.36

0.67

 

Non-relapse mortality

      

Rituximab dose (mg/m2)

      

 <1000

208

1

   

0.06

 1000–1999

109

0.90

0.54

1.51

0.70

 

 2000–3375

45

0.18

0.04

0.75

0.02

 

Progression/relapse

      

Rituximab dose (mg/m2)

      

 <1000

208

1

   

0.90

 1000–1999

109

1.01

0.63

1.61

0.97

 

 2000–3375

45

0.85

0.40

1.78

0.66

 

PFS

      

Rituximab dose (mg/m2)

      

 <1000

208

1

   

0.21

 1000–1999

109

0.99

0.70

1.39

0.94

 

 2000–3375

45

0.56

0.30

1.07

0.08

 

Mortality

      

Rituximab dose (mg/m2)

      

 <1000

214

1

   

0.052

 1000–1999

113

1.10

0.76

1.59

0.63

 

 2000–3375

47

0.43

0.21

0.90

0.02

 
  1. Abbreviations: GVHD graft-versus-host disease